ClinicalTrials.gg
Drug

Anti-CTLA-4 Monoclonal Antibody IBI310 clinical trials

Also written IBI310.

Its developmentBy Innovent Biologics, step by step11 company-led studies, furthest phase 3: when each phase was reached, its deals, target and what is ahead.
studies test it
17
open now
7
in phase 3
4
first study started
2018

How each study uses Anti-CTLA-4 Monoclonal Antibody IBI310 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Anti-CTLA-4 Monoclonal Antibody IBI310 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Development codes

IBI310
11

In one entry with another drug

Given together, or one or the other

sintilimab+IBI310+chemotherapy
2

Studies by the year they started

17 studies that test it; most in 2026 (5)

Studies that test Anti-CTLA-4 Monoclonal Antibody IBI310, by start year
YearStudies
20181
20191
20203
20214
20221
20231
20241
20265

By phase

A phase 1/2 study counts in both.

Phase 1
7
Phase 2
10
Phase 3
4

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 10 · Other 7

Innovent Biologics (Suzhou) Co. Ltd. (9) · Shanghai Pulmonary Hospital, Shanghai, China (2) · Peking University (2) · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (1) · Shanghai Zhongshan Hospital (1) · Second Affiliated Hospital, School of Medicine, Zhejiang University (1) · Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. (1)

Often tested with

Tested in the same studies.

Sintilimab (6) · Bevacizumab (1) · Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363 (1) · Cafelkibart (1) · Ipilimumab (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 2

Studies that test Anti-CTLA-4 Monoclonal Antibody IBI310.

Studies

Open first, then newest update. How each study uses Anti-CTLA-4 Monoclonal Antibody IBI310 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 17